Alyssa Mirabal, MD
Family Medicine · Edgewood, NMNPI 1043773005
Payments from drug & device makers
Across 42 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$123
- AbbVie$107
- Lilly USA, LLC$90
- AstraZeneca$70
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$61
- Astellas Pharma US Inc$59
- plus $346 from 14 others
What the payments were for
- Food & beverage$855100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $123 |
| AbbVie | 4 | $107 |
| Lilly USA, LLC | 4 | $90 |
| AstraZeneca | 4 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $61 |
| Astellas Pharma US Inc | 3 | $59 |
| Mylan Specialty L.p. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Baxter Healthcare | 1 | $36 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $26 |
| Viatris Specialty LLC | 1 | $22 |
| Exact Sciences | 1 | $22 |
| Merck | 1 | $20 |
| Pfizer | 1 | $20 |
| Angiodynamics, Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $18 |
| Coopersurgical, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
How this compares
$855 in reported general payments places this provider in the 75th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 17 | $36,863 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $22,740 |
| FarxigaDapagliflozin Propanediol | 22 | $21,967 |
| MounjaroTirzepatide | 20 | $20,838 |
| Spiriva RespimatTiotropium Bromide | 19 | $18,021 |
| TrulicityDulaglutide | 16 | $17,150 |
| OzempicSemaglutide | 11 | $16,182 |
| MyrbetriqMirabegron | 11 | $8,152 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $4,589 |
| Duloxetine Hcl | 35 | $2,880 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,502 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,837 |
| Levothyroxine Sodium | 137 | $1,707 |
| Atorvastatin Calcium | 126 | $1,690 |
| Rosuvastatin Calcium | 77 | $1,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $123 | $53,04528 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $70 | $47,20860 claims |
| Lilly USA, LLCMounjaro, Trulicity | $90 | $37,98836 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $8,15211 claims |
| AbbVieSynthroid | $107 | $26811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Edgewood
- Quito CarrAlbuquerque$10.4M
- Satkirin KhalsaAlbuquerque$5.8M
- Ellen KimAlbuquerque$2.2M
- Sally FisherAlbuquerque$1.8M
- Wendy JohnsonSanta Fe$270K
- Harold McFarlingFarmington$160K
- Effat BanikarimAlamogordo$86K
- Jeanne-Elyse CedenoLos Lunas$61K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.